Acumen Pharmaceuticals, Inc. (ABOS)

Verve Therapeutics Statistics

Total Valuation

ABOS has a market cap or net worth of $82.08 million. The enterprise value is -$86.39 million.

Market Cap	82.08M
Enterprise Value	-86.39M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025, before market open.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

ABOS has 60.57 million shares outstanding. The number of shares has increased by 12.92% in one year.

Current Share Class	60.57M
Shares Outstanding	60.57M
Shares Change (YoY)	+12.92%
Shares Change (QoQ)	+0.74%
Owned by Insiders (%)	15.11%
Owned by Institutions (%)	37.47%
Float	32.93M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.53
P/TBV Ratio	0.53
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.02, with a Debt / Equity ratio of 0.19.

Current Ratio	8.02
Quick Ratio	7.76
Debt / Equity	0.19
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-30.95

Financial Efficiency

Return on equity (ROE) is -55.68% and return on invested capital (ROIC) is -33.12%.

Return on Equity (ROE)	-55.68%
Return on Assets (ROA)	-31.31%
Return on Invested Capital (ROIC)	-33.12%
Return on Capital Employed (ROCE)	-68.38%
Revenue Per Employee	n/a
Profits Per Employee	-$1.91M
Employee Count	61
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -58.94% in the last 52 weeks. The beta is 0.14, so ABOS's price volatility has been lower than the market average.

Beta (5Y)	0.14
52-Week Price Change	-58.94%
50-Day Moving Average	1.25
200-Day Moving Average	1.59
Relative Strength Index (RSI)	48.03
Average Volume (20 Days)	588,560

Short Selling Information

The latest short interest is 1.51 million, so 2.49% of the outstanding shares have been sold short.

Short Interest	1.51M
Short Previous Month	1.71M
Short % of Shares Out	2.49%
Short % of Float	4.57%
Short Ratio (days to cover)	1.87

Income Statement

Revenue	n/a
Gross Profit	-106.62M
Operating Income	-126.61M
Pretax Income	-55.94M
Net Income	-116.25M
EBITDA	-126.55M
EBIT	-126.61M
Earnings Per Share (EPS)	-$1.93

Balance Sheet

The company has $149.15 million in cash and $29.78 million in debt, giving a net cash position of $168.16 million or $2.78 per share.

Cash & Cash Equivalents	149.15M
Total Debt	29.78M
Net Cash	168.16M
Net Cash Per Share	$2.78
Equity (Book Value)	155.52M
Book Value Per Share	2.57
Working Capital	135.63M

Cash Flow

In the last 12 months, operating cash flow was -$102.48 million and capital expenditures -$84,000, giving a free cash flow of -$102.56 million.

Operating Cash Flow	-102.48M
Capital Expenditures	-84,000
Free Cash Flow	-102.56M
FCF Per Share	-$1.69

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

ABOS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.92%
Shareholder Yield	-12.92%
Earnings Yield	-142.16%
FCF Yield	-125.42%

Analyst Forecast

The average price target for ABOS is $6.33, which is 367.16% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$6.33
Price Target Difference	367.16%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2